Last reviewed · How we verify
α-IFN
At a glance
| Generic name | α-IFN |
|---|---|
| Also known as | INTRONA |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients (NA)
- Circadian Clock Gene Expression in Periodontal Disease
- IFN-α in Relapse Prevention. (PHASE2)
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma (PHASE3)
- Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis (NA)
- Pentoxifylline in Patients With Ulcerative Colitis (PHASE2)
- Building an Assessment Model for Vitiligo Activity and Prognosis Using Peripheral Blood Cytokine Profiles
- Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- α-IFN CI brief — competitive landscape report
- α-IFN updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI